Mesoblast
Developing and commercialising allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases. Learn more
Launch date
Employees
Market cap
$692m
Enterprise valuation
$751m (Public information from Sep 2024)
Share price
AUD1.03 MSB.AX
Company register number 109431870
Melbourne Victoria (HQ)
Authorizing premium user...